Objective: To identify predictors of biochemical recurrence (BCR) after radical prostatectomy with or without standard pelvic lymphadenectomy in Korean men with high-risk prostate cancer.
INTRODUCTION
Although the incidence of prostate cancer detection in Asian men is much lower than the incidences observed in Caucasian men, it is clearly increasing. This is partly because of the now widespread use of the serum prostatespecific antigen (PSA) test but it may also reflect the changing dietary habits of Asian men. Korean men have also been shown to differ from Caucasian men, in that a higher proportion of the prostate cancers detected in Korean men are high grade; they are also more likely to show tumor extension into the seminal vesicles (1,2).
Several studies have shown that patients with prostate cancer with high pre-operative PSA levels, surgical or biopsy Gleason scores and/or clinical tumor categories can be considered to be at high risk of biochemical recurrence (BCR) (3 -5) . At present, as shown by analysis of the CaPSURE TM database, such patients with high-risk nonmetastatic prostate cancer are most frequently treated with a combination of hormonal therapy and radiation therapy (6) . Although androgen deprivation and radiotherapy are wellestablished treatment modalities for high-risk prostate cancer, it may also be possible that radical prostatectomy is more effective for such patients. Consequently, there is at present no consensus on the optimal treatment of high-risk non-metastatic prostate cancer.
In the present study, the rate of BCR in Korean men with one or more of the three high-risk factors who underwent radical prostatectomy with and without pelvic lymphadenectomy was estimated. To identify predictors of BCR in this patient cohort, the association between BCR and several preand post-operative variables was analyzed.
PATIENTS AND METHODS

PATIENTS
Approval of the study was obtained from the institutional review board. The data of patients who were treated by radical prostatectomy as the first-line treatment at our institution between 1997 and 2009 were reviewed retrospectively. All prostate cancer patients with high-risk factors, namely PSA levels .20 ng/ml, biopsy Gleason scores of 8 -10 or a clinical stage of T2c or higher, were evaluated (7). Patients who had received neoadjuvant or adjuvant treatment were excluded from the study.
In total, 199 patients were included in the study. All had negative bone scans and pelvic computed tomography or magnetic resonance images. The median age at surgery was 67.0 years (range: 46.0 -80.0). The median pre-operative PSA level was 12.6 ng/ml (range: 1.5 -357.0). The patients underwent open retropubic (n ¼ 175; 87.9%), pure laparoscopic (n ¼ 5; 2.5%) or robot-assisted laparoscopic (n ¼ 19; 9.5%) surgery based on the physician's choice. The laparoscopic or robot-assisted laparoscopic radical prostatectomy was performed with a transperitoneal approach. According to the standardized techniques, bilateral removal of the lymph nodes along the external vein and the obturator fossa was performed in 111 patients (55.8%). The number of nodes that were removed and examined ranged from 2 to 19 (median: 7.0). In our analysis of the results, we did not consider a minimum number of lymph nodes removed, due to the fact that the aim of the present study was to demonstrate the prognostic role of pelvic lymphadenectomy in our clinical experience. Lymph node metastases were found in four patients (3.6%).
HISTOLOGIC ANALYSIS
Tumor differentiation was denoted by the surgical Gleason score. The pathologic stage was assigned according to the 2002 TNM staging system. The key pathologic parameters were positive surgical margins, extracapsular extension, seminal vesicle invasion and lymph node metastasis. Surgical margins were considered to be positive when tumor foci were found by microscopy in the absence of macroscopically visible abnormalities. Lymph node positivity was defined as the presence of tumoral glands in at least one of the pelvic lymph nodes.
FOLLOW-UP
Patients were followed to determine whether PSA recurred. Beginning 6 -8 weeks after radical prostatectomy, the PSA level was measured every 3 months. The median follow-up period was 37.0 months (range: 1.0 -143.0). The endpoint of this study was the BCR, which was defined as a PSA concentration of 0.2 ng/ml that was found on two consecutive occasions.
STATISTICAL ANALYSIS
Comparisons between subject groups were performed by using the Student t-test or the x 2 test. BCR-free survival was determined from the date of surgery to the last follow-up visit. Survival curves were established by using the KaplanMeier method and compared by the log-rank test. Prognostic factors were established by univariate analysis, and those that were significant were entered into multivariate analysis using the Cox stepwise regression method. A P value ,0.05 was considered significant and all P values were two-sided. All tests were carried out with SPSS (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA) programs.
RESULTS
PATIENT CHARACTERISTICS AND POST-OPERATIVE NADIR PSA
Of 199 patients, only 85 (42.7%) had organ-confined disease. We found extracapsular extension in 107 (53.8%) patients and seminal vesicle invasion in 42 (21.1%) patients.
When patients were classified into two groups according to the nadir PSA level after radical prostatectomy, namely ,0.2 ng/ml (detection limit) and 0.2 ng/ml, 22 fell into the latter group. Of the four patients with lymph node metastases, three (75.0%) were in the 0.2 ng/ml group. The 0.2 ng/ml group was more likely than the ,0.2 ng/ml group to have two or three of the three highrisk determinants (P ¼ 0.008). It was also more likely to have pre-operative PSA levels exceeding 20 ng/ml (P ¼ 0.003), a surgical Gleason score of 8 (P ¼ 0.024), a positive surgical margin status (P ¼ 0.007), extracapsular extension (P ¼ 0.001) and seminal vesicle invasion (P ¼ 0.003). However, the two groups did not differ significantly in terms of the other variables that were tested (Table 1) .
When patients were divided into two subgroups according to pelvic lymphadenectomy, no statistically significant differences in clinical and pathological data between the two groups were observed (Table 2) .
BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
At the median follow-up period of 37.0 months, BCR was observed in 68 patients (34.2%). The median time to BCR Jpn J Clin Oncol 2011;41 (5) 657 was 11.0 months (range: 2.0 -88.0). The 1-, 3-and 5-year BCR-free survival rates were 79.6, 61.9 and 49.2%, respectively. The Kaplan -Meier curves revealed that BCR-free survival associated significantly with surgical Gleason score (P ¼ 0.040; log-rank test), surgical margin (P ¼ 0.001; 
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Radical prostatectomy in high-risk prostate cancer log-rank test), extracapsular extension (P , 0.001; log-rank test) and seminal vesicle invasion (P , 0.001; log-rank test) but not with other variables, including pelvic lymphadenectomy (Table 3 ). Figure 1 shows the Kaplan -Meier curves of the patients with high-risk prostate cancer when they were categorized according to the surgical Gleason score, surgical margin, extracapsular extension or seminal vesicle invasion. However, no significant difference in BCR-free survival rates was observed between pelvic lymphadenectomy vs. no pelvic lymphadenectomy (Fig. 2) .
MULTIVARIATE ANALYSIS
Multivariate Cox's proportional hazard analysis revealed that seminal vesicle invasion was the only significant independent prognostic factor of BCR-free survival (P ¼ 0.035, relative risk ¼ 1.81) ( Table 4 ). All other variables lost their statistical significance.
DISCUSSION
Compared with Caucasian men, Korean men are significantly more likely to develop moderate to poorly differentiated cancer, to present with a worse clinical stage and greater preoperative serum PSA level and to undergo surgery at a more advanced stage (1, 2) . This means that the surgical outcome is poorer for Korean men than for Caucasian men. In addition, compared with Caucasian men, Korean men show a higher rate of seminal vesicle invasion at all PSA ranges and clinical stages, as well as an overall lower rate of extracapsular extension and lymph node metastasis (1, 8) .
The most appropriate treatment for patients with high-risk prostate cancer remains controversial. Although radiation and hormonal therapy have been the preferred treatment modalities for this disease, radiation alone may be associated with a high rate of positive post-treatment biopsies (9) and an increased risk of metastatic dissemination in cases of persistent local disease (10) . In addition, combination therapy may not be of significant advantage for patients with high Gleason score disease (11) .
Several authors have reported good long-term outcomes for locally advanced prostate cancer when surgery is used as the initial treatment (12 -15) . Another benefit of radical prostatectomy is that it greatly improves pathologic staging, which assists with prognostication (16) . This is because pathologic features can only be determined properly after radical prostatectomy and multivariate analysis that includes pre-operative and pathologic features has revealed that only pathologic features are prognostic for progression. The improved prognostication associated with radical prostatectomy in turn enhances the ability to select those patients who may benefit from additional treatment (17) . Indeed, many patients who exhibit BCR after radical prostatectomy achieve salvage by radiation therapy (18 19) . In addition, recent studies have suggested that tumorreductive surgery of the primary bulk of the prostate improves the response to adjuvant hormonal therapy (12, 20 ).
Yet, another advantage of radical prostatectomy is that many of the patients who do exhibit PSA recurrences are not destined to develop clinical disease progression (21, 22) . These observations together show that primary tumor control significantly improves the therapy outcome, which means it is worthwhile assessing whether radical surgery could also improve the survival of patients with high-risk factors or even metastatic prostate cancer. The present study analyzed 199 Korean prostate cancer patients with one or more of the three high-risk factors who underwent radical prostatectomy with or without pelvic lymphadenectomy. Of these, 68 developed BCR. When the patient cohort was divided according to nadir PSA into the ,0.2 and 0.2 ng/ml groups, x 2 tests revealed that the latter group was more likely to have high pre-operative PSA levels, the presence of more than one of the three high-risk factors, a surgical Gleason score of 8, a positive surgical margin, extracapsular extension and seminal vesicle invasion. However, univariate analysis of the pre-operative clinical characteristics found that none could predict post-prostatectomy BCR. Unexpectedly, pelvic lymphadenectomy also did not correlate significantly with BCR-free survival. One possible explanation for this observation is that the four patients who had lymph node metastases did not receive adjuvant androgen deprivation therapy. Moreover, our patients were not subjected to extended pelvic lymphadenectomy; analysis of the patients in the Surveillance, Epidemiology, and End Results Program (1988 -91) has shown that more extensive pelvic lymphadenectomy may reduce the risk of prostate cancer-specific death in the long term (23) . However, DiMarco et al. (24) could not confirm that the extent of pelvic lymphadenectomy affects prostate cancer outcome in node-negative men. In fact, since it remains unclear whether pelvic lymphadenectomy actually has a therapeutic role in prostate cancer management (25) , it may well be that our findings reflect the true lack of impact of pelvic lymphadenectomy on BCR after radical prostatectomy in high-risk patients. A multiinstitutional, randomized clinical trial is needed to determine the therapeutic value of extended pelvic lymphadenectomy.
Univariate analysis revealed that all of the pathologic variables, namely surgical Gleason score, surgical margin, extracapsular extension and seminal vesicle invasion, were potentially prognostic of post-prostatectomy BCR. However, multivariate analysis revealed that only seminal vesicle invasion was a significant independent prognostic factor of BCR-free survival. Since, indeed, BCR after initial therapy for prostate cancer is typically the first evidence of disease progression and it precedes any clinical manifestation of metastatic disease by 5 -7 years (26), early adjuvant or salvage therapy may be considered in these patients after radical prostatectomy. However, because the natural history of prostate cancer is variable and we currently have no accurate means of identifying those who will progress, it will be necessary to conduct further studies to find useful prognostic parameters that will allow high-risk patients who could benefit from early salvage or adjuvant therapy to be identified at an early stage of the disease.
Several limitations of this study should be considered. First, it was a retrospective study, which means it is likely to suffer from the biases that are typical of such studies, including patient referral, selection or inclusion. However, one advantage of this study is that the frequency of PSA measurements did not vary. This is important since the frequency of PSA measurement can affect BCR outcome. Secondly, the median follow-up of the cohort was only 37.0 months at the time of analysis, which impeded our ability to analyze associations between post-prostatectomy BCR in high-risk patients and progression variables. Although BCR-free survival rate may be used as an endpoint and an indicator of the success of surgery, the clinical significance of this endpoint needs to be evaluated by employing a longer follow-up period, as this would allow us to determine whether patients with BCR who are still at risk of cancer death actually die of prostate cancer. Nonetheless, serum PSA is the most sensitive indicator of recurrence after definitive local therapy for prostate cancer and BCR is widely used as an early endpoint to assess treatment success and to prompt the initiation of secondary therapy. Finally, pelvic lymphadenectomy was not performed randomly in our cohort. However, diminishing the significance of this is that the groups with and without pelvic lymphadenectomy did not exhibit significant differences in clinical and pathologic characteristics.
